Announcement
10.02.2012


NeuroSearch A/S (NEUR) hereby updates the company’s financial calendar for 2012
as a consequence of the changed date for the Annual General Meeting:

Financial calendar for 2012

28 February 2012 Annual Report 2011
10 April 2012 Annual General Meeting
25 April 2012 Interim report for the first three months of 2012
30 August 2012 Interim report for the first six months of 2012
15 November 2012 Interim report for the first nine months of 2012

Patrik Dahlen
CEO

Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097

About NeuroSearch
NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on
NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is to complete the development and
subsequently to market Huntexil®, a unique drug in clinical Phase III for the
treatment of the motor symptoms of Huntington’s disease.
As a consequence of the restructuring of NeuroSearch that was announced 27
September 2011, the company also has a portfolio of assets for outlicensing or
divestment.

Fonds.03-12 - Financial calendar 2012 - uk.pdf